MedTrace Logo

Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC

NCT05134532 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-04-26

No results posted yet for this study

Summary

To investigate efficacy and toxicity of regorafenib after treatment with atezolizumab and bevacizumab combination

Conditions

Interventions

DRUG

regorafenib

Regorafenib 160 mg orally every day for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off) plus best supportive care

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • CHA University

    lead OTHER

Principal Investigators

  • Cheon · CHA Bundang Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-24
Primary Completion
2024-10-30
Completion
2024-10-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05134532 on ClinicalTrials.gov